Exciting Leadership Change at Synendos Therapeutics
Synendos Therapeutics, a forward-thinking biotechnology firm focused on developing innovative therapies for neuropsychiatric disorders, has recently announced a significant addition to its leadership team. The company has appointed Dr. George Garibaldi as Chief Medical Officer (CMO). This strategic decision comes at a crucial time as Synendos gears up to enter Phase 2 clinical trials for its pioneering drug candidate, SYT-510.
Expertise That Makes a Difference
Dr. Garibaldi brings with him over 30 years of extensive experience in clinical development, particularly in Central Nervous System (CNS) disorders. His substantial expertise has been honed through notable positions at leading pharmaceutical companies like Roche, Novartis, and Janssen. During his tenure, he played a pivotal role in the rollout of groundbreaking treatments such as Ocrevus for multiple sclerosis and Exelon for Alzheimer's disease.
A Track Record of Success
As a co-founder of Noema Pharma, Dr. Garibaldi successfully led the initiative to revitalize and advance neglected CNS assets, securing vital venture funding and pushing these through critical clinical trials. His contributions are significant, with more than 100 peer-reviewed publications and numerous clinician- and patient-reported outcome measures to his name. Colleagues recognize him as a collaborative leader committed to enhancing mental healthcare through innovative solutions.
A Vision for Transformation
In his new role, Dr. Garibaldi expressed his enthusiasm for joining Synendos by highlighting the urgent need for innovation in mental health therapies. He stated, "Mental health and brain health have for far too long been underserved by traditional drug development models. Synendos is uniquely positioned to harness new target pursuits while reshaping the way clinical trials are conducted and outcomes measured."
Innovative Approach to Drug Development
Dr. Garibaldi's commitment aligns perfectly with Synendos' mission to revolutionize mental health treatment. The company’s innovative approach involves utilizing modulation of a novel target within the endocannabinoid system, which could restore natural brain functioning – a promising solution for conditions such as anxiety disorders and PTSD.
The Future of Mental Health Treatment
SYT-510, the company's leading candidate, belongs to a novel category of drugs known as Selective Endocannabinoid Re-uptake Inhibitors (SERIs). SERIs are considered first-in-class chemical entities that possess the potential to effectively manage a broad spectrum of symptoms while maintaining a favorable tolerability profile. This allows more patients to remain on therapy longer, ultimately improving their quality of life.
Why This Matters
This transformational approach not only aims to enhance treatment efficacy but also directly addresses an unmet need—chronic tolerability. By facilitating a treatment path that prioritizes patients' functional needs, Synendos aims to make meaningful strides in neuroscience therapies.
Moving Forward
With Dr. Garibaldi's expertise and leadership at the helm, Synendos Therapeutics is poised to continue its commitment to advancing the next generation of therapies that could significantly impact the lives of patients suffering from mental health issues. The company's journey is one of determination, innovation, and a steadfast dedication to the well-being of individuals facing neuropsychiatric disorders.
Frequently Asked Questions
Who is the new Chief Medical Officer at Synendos?
Dr. George Garibaldi has been appointed as the new CMO at Synendos Therapeutics.
What is the significance of SYT-510?
SYT-510 is Synendos' lead drug candidate, designed to address neuropsychiatric disorders through a novel mechanism in the endocannabinoid system.
How does Synendos enhance treatment for mental health?
By focusing on patient-centered approaches and utilizing innovative drug mechanisms, Synendos aims to provide more effective and tolerable therapies.
What is the potential of SERIs?
Selective Endocannabinoid Re-uptake Inhibitors (SERIs) have the potential to offer significant therapeutic benefits while enhancing patient adherence to treatment.
How can I contact Synendos for more information?
For inquiries, please reach out to Simon Russell at simon.russell@synendos.com or call +41 79 138 5840.
